Zimbabwe - Prevalence of HIV, total (% of population ages 15-49)

Prevalence of HIV, total (% of population ages 15-49) in Zimbabwe was 12.70 as of 2018. Its highest value over the past 28 years was 27.80 in 1996, while its lowest value was 12.70 in 2018.

Definition: Prevalence of HIV refers to the percentage of people ages 15-49 who are infected with HIV.

Source: UNAIDS estimates.

See also:

Year Value
1990 17.00
1991 20.40
1992 23.20
1993 25.40
1994 26.80
1995 27.60
1996 27.80
1997 27.50
1998 26.90
1999 26.00
2000 25.00
2001 23.80
2002 22.60
2003 21.30
2004 20.10
2005 19.00
2006 18.00
2007 17.10
2008 16.40
2009 15.80
2010 15.40
2011 15.00
2012 14.70
2013 14.40
2014 14.10
2015 13.80
2016 13.40
2017 13.10
2018 12.70

Limitations and Exceptions: The limited availability of data on health status is a major constraint in assessing the health situation in developing countries. Surveillance data are lacking for many major public health concerns. Estimates of prevalence and incidence are available for some diseases but are often unreliable and incomplete. National health authorities differ widely in capacity and willingness to collect or report information.

Statistical Concept and Methodology: HIV prevalence rates reflect the rate of HIV infection in each country's population. Low national prevalence rates can be misleading, however. They often disguise epidemics that are initially concentrated in certain localities or population groups and threaten to spill over into the wider population. In many developing countries most new infections occur in young adults, with young women especially vulnerable. Data on HIV are from the Joint United Nations Programme on HIV/AIDS (UNAIDS). Changes in procedures and assumptions for estimating the data and better coordination with countries have resulted in improved estimates of HIV and AIDS. The models, which are routinely updated, track the course of HIV epidemics and their impact, making full use of information in HIV prevalence trends from surveillance data as well as survey data. The models take into account reduced infectivity among people receiving antiretroviral therapy (which is having a larger impact on HIV prevalence and allowing HIV-positive people to live longer) and allow for changes in urbanization over time in generalized epidemics. The estimates include plausibility bounds, which reflect the certainty associated with each of the estimates.

Aggregation method: Weighted average

Periodicity: Annual


Topic: Health Indicators

Sub-Topic: Risk factors